Helix logo in white and blue


Lead a more targeted approach to drug development, testing, and commercialization by understanding the size of your addressable patient population in terms of the incidence, prevalence, and spread of disease.

Prevalence of non-alcoholic steatohepatitis (NASH) since 2012

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.


Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ultrices dui sapien eget mi proin sed libero enim sed.


Lorem ipsum dolor sit amet.

Lorem ipsum dolor sit amet.

Lorem ipsum dolor sit amet.

Lorem ipsum dolor sit amet.

Lorem ipsum dolor sit amet.

Lorem ipsum dolor sit amet.

Lorem ipsum dolor sit amet.

Power your decision-making

with bespoke and intuitive intelligence boards

Each intelligence board leverages integrated and enriched data
from diverse sources, allowing you to:


No items found.


  • Disease prevalence and incidence
  • Disease risk factors  
  • Mortality and morbidity rates
  • Surveillance trends
  • Population demographics  


  • Insights at a regional, state, or country level
  • Demographic trends and disparities within, e.g., different age, sex, race, and ethnicity categories
  • Disease causation and comorbidity relationships, aided by filters for disease etiology and risk factors

Maintain a clear view of the dynamics of disease distribution over the entire lifecycle of your product with user-defined data updates.

Use cases

Estimate the market size for a new therapy to assess commercial opportunity

Tailor access strategies, justify pricing decisions, and negotiate reimbursement agreements

Inform Health Economics and Outcomes Research (HEOR)

Determine the size and characteristics of the patient population most likely to benefit from an intervention

Select clinically relevant endpoints, outcome measures, and comparators for clinical trials

Facilitate clinical trial recruitment by identifying regions or populations with high disease prevalence

Leverage Real-World Evidence (RWE) to complement clinical trial data, evaluate treatment effectiveness in real-world settings, and inform clinical decision-making

Develop educational materials about disease prevalence, risk factors, and treatment options

Support scientific communications and publications

Delivered through Helix.

Modular knowledge base

  • Interactive data visualizations for easy self-serve analysis and insight surfacing

  • Comprehensive opinion leader profiles for effective interaction planning and engagement

  • Multiple data export options for rapid insight sharing across your business

  • Customizable, modular knowledge bases with no user limits

A VISFO "Key Opinion Leader (KOL) intelligence board" displayed on both a desktop and mobile screen. The board includes an interactive KOL map, as well as the results of a KOL influence analysis."